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is likely to be the cause of bacterial vaginosis and 
that Koch’s postulates for disease causation are 
inadequate for describing potential causal rela-
tionships in this syndrome. Bacterial vaginosis 
probably results from infection with complex com-
munities of bacteria that consist of metaboli-
cally interdependent (syntrophic) species. Diseases 
caused by uncultivated microbes or communities 
of microbes are not amenable to the application of 
Koch’s postulates in their original formulation2; 
therefore, we must build a case for causation on the 
basis of a concordance of scientific evidence.3
David N. Fredricks, M.D.
Fred Hutchinson Cancer Research Center
Seattle, WA 98109
dfredric@fhcrc.org
Jeanne M. Marrazzo, M.D., M.P.H.
University of Washington
Seattle, WA 98195
Swidsinski A, Mendling W, Loening-Baucke V, et al. Adherent 
biofilms in bacterial vaginosis. Obstet Gynecol 2005;106:1013-23.
Evans AS. Causation and disease: a chronological journey. 
New York: Plenum Medical Book, 1993:238.
Fredricks DN, Relman DA. Sequence-based identification of 
microbial pathogens: a reconsideration of Koch’s postulates. 
Clin Microbiol Rev 1996;9:18-33.
1.
2.
3.
Azithromycin versus Penicillin for Early Syphilis
To The Editor: In their study on the treatment of 
early syphilis, Riedner et al. (Sept. 22 issue)1 con-
cluded that the wider use of oral azithromycin 
should be encouraged as part of syphilis-control 
programs in developing countries. Whereas this 
conclusion would appear to be rational on the 
basis of the authors’ results, we believe that there 
are other factors that should be considered before 
opting for such a strategy.
Although the authors acknowledged the po-
tential for the emergence of azithromycin-resis-
tant Treponema pallidum, ongoing monitoring for 
such resistance, as they suggested, requires mo-
lecular-sequencing techniques,2 which are unavail-
able in most developing countries. More impor-
tant, the inability of azithromycin to cross the 
placenta3 limits its use in the prevention of con-
genital disease. Treatment of seropositive moth-
ers with oral azithromycin, after routine antena-
tal screening, could result in declining maternal 
titers on the rapid plasma reagin test without af-
fecting the potential for fetal infection.
Since the prevention of congenital syphilis re-
mains a major objective of control programs and 
is a current focus for global elimination activities,4 
we believe that azithromycin has only a limited 
role in the management of syphilis in resource-
constrained settings.
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To the Editor: Riedner and colleagues report 
that azithromycin is equivalent to penicillin G 
benzathine in treating early syphilis and may be 
useful in developing countries in which use of 
penicillin G benzathine is problematic, and they 
alert us about the cases of azithromycin-resistant 
T. pallidum. In Brazil, we struggle even with inex-
pensive drugs, such as penicillin G benzathine; 
azithromycin is not widely available and can be 
10 times as expensive as penicillin G benzathine. 
We believe that it is not wise to change from a 
known, inexpensive drug with few cases of resis-
tance after a half century of use1 to a more expen-
sive, unfamiliar drug that has already shown 
resistance after a few years of use.2 Thus, the 
implementation of azithromycin in developing 
countries remains prohibitive because of the cost 
and because of the possibility of resistance, and 
this drug should not be used as a first choice yet.
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To the Editor: Riedner and colleagues demon-
strated the successful treatment of early syphilis 
with azithromycin. Holmes’s accompanying edi-
torial laments the absence of prospective data on 
patients treated for early syphilis with azithro-
mycin and the influence of molecularly defined 
azithromycin-resistant T. pallidum on treatment 
outcomes.1
In San Francisco, where an estimated 56 per-
cent of circulating strains of T. pallidum were re-
sistant to azithromycin in 2004,2 we conducted 
a randomized, controlled trial of azithromycin 
(1 g given orally as a single dose) as compared 
with penicillin G benzathine (2.4 million units 
intramuscularly) in sexual contacts of persons 
with infectious syphilis; our aim was to compare 
the efficacy of the two drugs for the treatment 
of incubating syphilis. A data safety monitoring 
board (DSMB) supervised the study.
After two treatment failures in the 12 patients 
receiving azithromycin as compared with none 
in 13 patients receiving penicillin, the DSMB ter-
minated the study (P = 0.18, by Fisher’s exact test). 
Although it was a small study sample (n = 25), our 
data suggest that azithromycin was inferior to 
penicillin in the presence of high community lev-
els of azithromycin-resistant T. pallidum. Although 
we have feasible methods to monitor macrolide 
resistance in T. pallidum, routine surveillance is not 
currently supported by federal agencies.
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The authors reply: We agree with Ballard et al. 
that further studies are needed before azithromy-
cin can be recommended for the treatment of 
syphilis in pregnancy, although studies in women 
undergoing cesarean section have shown that az-
ithromycin does cross the placenta.1
Resistance is clearly a concern in view of the 
high proportion of strains of T. pallidum found 
among men who have sex with men in the United 
States and Ireland that contain mutations that 
may confer resistance to macrolides. The clinical 
significance of this mutation has not been defini-
tively established, although the small study by 
Klausner et al.2 provides some support for such 
a link. The results of our trial suggest that azith-
romycin resistance is not currently a clinically sig-
nificant problem among heterosexual patients in 
Tanzania. We recognize that most laboratories in 
Africa do not have the facilities to identify muta-
tions in local strains of T. pallidum. In view of the 
considerable advantages that would be conferred 
by a single-dose oral treatment for syphilis, how-
ever, we believe further studies are warranted to 
study the geographic distribution and clinical sig-
nificance of strains bearing this mutation.
We do not agree with Savaris and Abeche that 
azithromycin is too expensive to be used for the 
treatment of syphilis in developing countries. 
Generic supplies of the drug, made in India, have 
been available for some years at a cost of approxi-
mately $1.20 for a 2-g dose.3 Azithromycin came 
off patent in the United States in November 2005. 
Although penicillin G benzathine is an inexpen-
sive drug, the cost of administering it has to in-
clude the cost of the needle and syringe.
Despite the issues raised by the correspondents, 
we consider that single-dose azithromycin may 
have a place in the treatment of early syphilis and 
in the management of genital-ulcer disease at the 
primary health care level in developing countries.
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The editorialist replies: It is striking that the 
first randomized trial demonstrating azithromy-
cin’s efficacy for early syphilis in Africa was con-
ducted virtually simultaneously with the emergence 
of azithromycin-resistance mutations in T. palli-
dum in all five cities where such mutations were 
sought in the United States and Ireland. This may 
represent a world record for the adaptation of a 
pathogen to an antimicrobial agent newly proved 
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effective to treat it — and this by an organism 
not previously known for its propensity to develop 
resistance to other antimicrobial agents. Reserva-
tions about the use of azithromycin for the treat-
ment of early syphilis are clearly warranted.
Fortunately, T. pallidum remains fully suscep-
tible to penicillin G benzathine worldwide, and 
the forthcoming 2006 Sexually Transmitted Dis-
ease Guidelines from the Centers for Disease Con-
trol and Prevention will correctly recommend that 
“penicillin G, administered parenterally, is the 
preferred drug for treatment of all stages of syphi-
lis” and that the recommended regimen for adults 
with primary, secondary, or early latent syphilis 
is “benzathine penicillin G 2.4 million units IM 
[intramuscular] in a single intramuscular dose.”
King K. Holmes, M.D., Ph.D.
University of Washington
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Cost-Effectiveness of ICDs
To the Editor: The cost-effectiveness of im-
plantable cardioverter–defibrillator (ICD) therapy 
reported by Sanders et al. (Oct. 6 issue)1 is overly 
optimistic, because it does not fully account for 
several factors that raise the costs and lower the 
effectiveness of this therapy. The authors assumed 
a constant benefit of the ICD during the patient’s 
lifetime, whereas in previous investigations, the 
benefit declined, with a convergence of survival 
curves by seven to eight years.2 The assumed prob-
ability of lead-related complications (2.4 percent 
over 20 months) underestimates the spectrum and 
frequency of serious complications (up to 14 per-
cent in the Sudden Cardiac Death in Heart Fail-
ure Trial [SCD-HeFT]).3 The high frequency of re-
calls of devices and the consequent interventions 
are not accounted for.4 The base-case assumption 
of an equivalent quality of life among patients 
who received an ICD and the control patients does 
not account for the adverse effect of ICD shocks 
(31 percent in SCD-HeFT)3 or for the discomfort, 
inconvenience, and the loss of time and income 
due to the implantation procedure and the need 
for replacement of the device, the checking and 
programming of the device before and after many 
forms of surgery, and, because of the presence of 
the device, the exclusion of several types of diag-
nostic procedures, treatments, employment, and 
recreation. The inclusion of these factors, in ad-
dition to those noted by Goldman in his edito-
rial,5 would unfavorably affect the cost-effective-
ness of ICDs.
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To the Editor: The study by Sanders et al. of the 
cost-effectiveness of ICDs exemplifies the skilled 
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